2020
A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection
Kroon EDMB, Ananworanich J, Pagliuzza A, Rhodes A, Phanuphak N, Trautmann L, Mitchell JL, Chintanaphol M, Intasan J, Pinyakorn S, Benjapornpong K, Chang JJ, Colby DJ, Chomchey N, Fletcher JLK, Eubanks K, Yang H, Kapson J, Dantanarayana A, Tennakoon S, Gorelick RJ, Maldarelli F, Robb ML, Kim JH, Spudich S, Chomont N, Phanuphak P, Lewin SR, de Souza MS, Teams F. A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. Journal Of Virus Eradication 2020, 6: 100004. PMID: 33251022, PMCID: PMC7646672, DOI: 10.1016/j.jve.2020.100004.Peer-Reviewed Original ResearchAcute HIV infectionAntiretroviral therapyTreatment interruptionViral loadAcute HIV-1 infectionHIV RNA copies/Open-label pilot studyPeripheral blood mononuclear cellsControl HIV replicationSubsequent treatment interruptionTotal HIV DNASerious adverse eventsHIV viral loadPlasma viral loadRNA copies/HIV-1 infectionBlood mononuclear cellsCopies/mLProportion of participantsCell-associated RNAAlternative treatment strategiesHistone deacetylase inhibitorsVL reboundHIV RNAViral rebound
2011
Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy
Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E, Fuchs D, Palmer S, Price RW. Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy. The Journal Of Infectious Diseases 2011, 204: 1936-1945. PMID: 22021620, PMCID: PMC3209817, DOI: 10.1093/infdis/jir667.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsHIV-1 RNAImmune activationRaltegravir intensificationRNA levelsPlasma human immunodeficiency virus type 1 (HIV-1) RNACSF HIV-1 RNA levelsMedian HIV-1 RNA levelT-cell surface antigen expressionHuman immunodeficiency virus type 1 (HIV-1) RNAOpen-label pilot studySingle-copy assayHIV RNA levelsCerebrospinal fluid infectionHIV-1 infectionCentral nervous systemBaseline viral suppressionSurface antigen expressionT cell activationCSF neopterinIntrathecal immunoactivationSuppressive therapyAntiretroviral therapyTreatment intensificationViral suppression